A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Researchers are looking for new ways to treat advanced, high-grade ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body (metastatic) and may not be removed with surgery. High-grade means the cancer cells grow and spread quickly. This trial includes types of OC that started in cells that cover the ovaries, in the lining of the belly, or in the fallopian tubes. The usual treatment for high-grade OC may include one or both of these: * Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing. * Bevacizumab, which is a targeted therapy that works to control how specific types of cancer cells grow and spread and targets tumor blood vessels. Researchers want to learn about the trial medicine, raludotatug deruxtecan (also called R-DXd or MK-5909), when given with and without bevacizumab and how participants respond to it. R-DXd is an antibody drug conjugate (ADC). An ADC is a type of medicine that attaches to a specific target on cancer cells and delivers treatment to destroy those cells. The goals of this trial are to learn if participants who receive R-DXd, with or without bevacizumab, live longer overall and without their cancer growing or spreading compared to those who receive usual treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zaawansowany rak jajnika, otrzewnej lub jajowodu, szybko rosnący typ komórek (wysoko zróżnicowany)
- •Otrzymała wcześniej chemioterapię na bazie platyny (co najmniej 4 cykle) i choroba reaguje na platynę
- •Otrzymała lek z grupy inhibitorów PARP jako podtrzymanie po pierwszej chemioterapii i nowotwór rosnął podczas lub do 42 dni po skończeniu tego leku
- •Ogólny stan zdrowia oceniony na 0-1 w skali ECOG (może wychodzić z domu i wykonywać zwykłe czynności)
- •Wyzdrowiała z niepożądanych skutków ubocznych poprzednich terapii
✗ Disqualifies
- •Inne typy raka jajnika (jasnokomórkowy, śluzowy, sarkomatoidalny) lub rak nisko zróżnicowany
- •Historia zaburzeń krzepnięcia, krwawień, krwawienia z płuc lub krwawienia z przewodu pokarmowego w ciągu ostatnich 6 miesięcy
- •Niekontrolowana lub poważna choroba serca i naczyń
- •Poważne problemy z płucami, w tym w ostatnich 3 miesiącach (zatory płucne, ciężka astma, POChP, zwłóknienie) lub przebyta operacja usunięcia płuca
- •Ciągłe długotrwałe stosowanie sterydów (z pewnymi wyjątkami)
- •Zatkanie jelit związane z rakiem, przetoka żołądkowo-jelitowa lub przekłucie przewodu pokarmowego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 16, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (4)
MemorialCare Orange Coast Medical Center ( Site 0032)
Fountain Valley, United States
Orlando Health Cancer Institute ( Site 0018)
Orlando, United States
Sourasky Medical Center ( Site 2701)
Tel Aviv, Israel
National Cheng Kung University Hospital ( Site 5304)
Tainan, Taiwan
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.